Switch to
More onapp

How to use scorecard? Learn more

Hikal Ltd

HIKAL
Health CarePharmaceuticals
SmallcapWith a market cap of ₹3,709 cr, stock is ranked 784
Moderate RiskStock is 2.68x as volatile as Nifty
300.850.10 (+0.03%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹3,709 cr, stock is ranked 784
Moderate RiskStock is 2.68x as volatile as Nifty

Key MetricsEdit

No LabelNo Label
51.79
PB RatioPB Ratio
3.27
Dividend YieldDiv. Yield
0.40%
Sector PESector PE
51.76
Sector PBSector PB
5.90
Sector Div YldSctr Div Yld
0.56%

Forecast & RatingsDetailed Forecast 

100%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Hikal Limited is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharmaceutical ingredients and contract research activities. The Company offers pharmaceuticals and agrochemicals.

Investor PresentationView older 

Aug 8, 2023

PDF
View Older Presentations

Financial TrendFinancial statements 

20202021202220231.511.731.952.030.080.130.160.08
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Appointment 
Announced OnApr 15, 2024

Hikal Limited has informed the Exchange regarding Appointment of Dr. K Suresh Babu as Head-Quality of the company w.e.f. April 15, 2024. | Download

Hikal Limited has informed the Exchange regarding Appointment of Dr. K Suresh Babu as Head-Quality of the company w.e.f. April 15, 2024. | Download

Cessation 
Announced OnApr 15, 2024

Hikal Limited has informed the Exchange regarding Cessation of Dr. T Devanathan as Vice President Quality (Pharma) of the company w.e.f. April 15, 2024. | Download

Hikal Limited has informed the Exchange regarding Cessation of Dr. T Devanathan as Vice President Quality (Pharma) of the company w.e.f. April 15, 2024. | Download

Cash Dividend 
Ex. DateFeb 20, 2024

Interim • Div/Share: ₹ 0.6

See all events